Fragment-to-Lead Medicinal Chemistry Publications in 2021

Louise Walsh*, Daniel A. Erlanson, Iwan J.P. de Esch, Wolfgang Jahnke, Andrew Woodhead, Ella Wren

*Corresponding author for this work

Research output: Contribution to JournalReview articleAcademicpeer-review

16 Downloads (Pure)

Abstract

This Perspective is the seventh in an annual series that summarizes successful Fragment-to-Lead (F2L) case studies published in a given year. A tabulated summary of relevant articles published in 2021 is provided, and features such as target class, screening methods, and ligand efficiency are discussed, both for the 2021 examples and for the combined examples over the years 2015-2021. In addition, trends and new developments in the field are summarized. In particular, the use of structural information in fragment-based drug discovery is discussed.

Original languageEnglish
Pages (from-to)1137-1156
Number of pages20
JournalJournal of medicinal chemistry
Volume66
Issue number2
Early online date9 Jan 2023
DOIs
Publication statusPublished - 26 Jan 2023

Bibliographical note

Publisher Copyright:
© 2023 American Chemical Society.

Fingerprint

Dive into the research topics of 'Fragment-to-Lead Medicinal Chemistry Publications in 2021'. Together they form a unique fingerprint.

Cite this